Details of Drug Interaction | MecDDI

Drug General Information (ID: DDI9M5HLOW)
Drug Name			Maraviroc		Drug Info		Azilsartan medoxomil		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Anti-Hiv Agents				Antihypertensive Agents
Structure

Mechanism of Maraviroc-Azilsartan medoxomil Interaction (Severity Level: Moderate)
Additive hypotensive effects Click to Show/Hide Mechanism Graph

Drug Name		Maraviroc				Azilsartan medoxomil
Mechanism 1		Antihypertensive agent				Antihypertensive agent Angiotensin II receptor Antagonist
Key Mechanism Factor 1
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Maraviroc and Azilsartan medoxomil
Mechanism 2		Hypotensive effects				Antihypertensive agent Angiotensin II receptor Antagonist
Key Mechanism Factor 2
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Maraviroc and Azilsartan medoxomil

Recommended Action
Management		Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.